Presentation given to VINNOVA visit, November 2012

1. 1

2. Life Science Investment Organisation
Dr Hakim Yadi
November 30th 2012
2

3. Who are UKTI?
• Team that covers:
– Trade (UK-based companies selling overseas)
– Investment (Foreign Owned Companies investing in the UK)
3

4. Who are UKTI?
• When working on new investment, we cover:
– Politics, policy and barriers to growth
– Access to Ministers
– Campaigns
– R&D collaborations
– Project management of new investment
projects
• We are organised sectorally, including Life Science and Health
– Backed up by sector experts in sub segments
– Within this there is currently a special focus on life science and
health: the Life Sciences Investment Organisation (LSIO)
November 07, 2012 4

5. How Do We Promote
Investment Into The UK?
5

6. UK Inward Investment Network: Our Overseas Network
232 FTE (FDI)
3 Regional Hubs (Hong Kong, New York & Paris)
Source: Great Britain & Northern Ireland – UK Inward Investment Network, Our Team, July 2012
6

7. Source Markets For Inbound FDI 2007-2011
Source: fDi Markets, a service from the Financial Times September 2012, Microsoft Map Point
7

8. Sector Trends
UK Inward Investment: Life Sciences
800
Forecast
700
Life Sciences
600
500
Projects
400
300
200
100
0
8

9. Using the UK Life Science Strategy
to support international UK Offers
9

10. A sector under pressure
10

11. Why invest in UK Life Sciences?
The UK Life Science Strategy – a
response to a challenged sector.
The Life Sciences Strategy is the UK’s
response to a global problem of rising
costs and complexity of research and
development, and the need for
products and services to address
patients needs and the needs of an
ageing population.
11

12. We have the know-how
• 4 of the world’s top 10 universities
• Leading country in the G8 for research productivity
• The UK accounts for 6% of world publications and
a global share of 14% of the most-cited papers
• Scientists in the UK have been awarded more than
76 Nobel Prizes (35 and counting for medical
research)
• The UK has a rich heritage in transformative
science with a proven track record in drug
discovery – more than 20% of biopharmaceuticals
in development originated in the UK
12

13. Life Science Investment Organisation
• UKTI has established a new initiative – the
Life Science Investment Organisation (LSIO)
• The LSIO is charged with:
– Creating a clearer presentation of the
UK’s capabilities and offering to the
Global Life Sciences sector
– Targeted business development based on
UK strengths and global market needs
– Creating and empowering a community of
UK Life Science ambassadors
13

14. LSIO Targeted Business Development
• Plans based on areas of differentiation for the UK Life Science base:
− Dementia Neurology
− Stratified Medicine
− Experimental Medicine
− Medical Technologies and convergence
• UKTI will target both existing Life Science companies (e.g. Pharma) and
disruptive companies (e.g. telehealth/eHealth) that would benefit from
working with the UK
• In addition, UKTI will work with the investment community to understand
how the UK’s science offering can generate new investment-fund related
opportunities
• The business plan will be continuously refreshed and updated on a monthly
cycle
14

15. Delivering the Targeted business development campaign
• Step 1: Define UK offer and create top line messages. Based on:
− Basic and applied research, Academic-clinical partnerships with industry,
Patient stratification and NHS access, SMEs and industry sectors
− Step 2: Create selling and delivery toolkit
− Step 3: Identify companies and individuals to target with the proposition
− Step 4: Engage companies, present the proposition and follow through
on investment opportunities
− Step 5: Report back to stakeholders on any gaps in the proposition to
ensure the UK Life Science Strategy is in tune with industry needs
15

16. Creating a community
 Promotion of the UK Life Science strategy
will not happen fast enough or reach the
audience we hope to through UKTI alone Global Life
Sciences
 UKTI have identified a community that
can benefit from being part of an
extended virtual team, these individuals
will be approached to help promote the
unified proposition
 We need to change the misconceptions of
the sector and promote positive messages
of UK success
16

17. How can we help
17

18. Working in partnership
• UKTI combines the expertise of professional trade and industry advisers in the
UK alongside a global network of experts based in British diplomatic offices
overseas, giving you access to a well-connected presence on the ground at
home and in the UK.
• Our practical help and advice for inward investment is free and confidential.
We work closely with other government departments and the wider UK Life
Science community to provide excellent service and present the best UK offer.
• Your business’ journey is important to us, from when your business is first
considering making an investment in the UK to once it is well established – we
are here to support your business’ ongoing and future activities
18

19. Working in partnership
• UKTI has established a dedicated unit focused on UK life sciences. The UKTI
Life Science Investment Organisation (LSIO) is your partner acting as a simple
interface to the UK Life Science sector.
• The LSIO is your guide to identifying research, development and delivery
partners and will support you through every step of investing in and working
in the UK.
• “UKTI connects your business to subject matter and experts across the Life
Sciences and healthcare sector in the UK.”
19

20. 20